Navigation Links
Study Uncovers Key Success Factors and Common Failure Points for Launching New Metabolic Products in Today's Competitive Healthcare Market
Date:9/2/2011

CHAPEL HILL, N.C.,  Sept. 2, 2011 /PRNewswire/ -- One of the more difficult aspects of planning a new metabolic product launch is balancing the different resource and investment allocations that are needed to prepare the marketplace for a new product.  In particular, organizations wrestle with allocating the appropriate resources for informing key stakeholders as well as other critical launch activities that are carried out across different functional areas.

How does a pharma or biotech company successfully launch a new product into a crowded, competitive marketplace?

Among the several other strategies is this: Many companies seek to gain greater commercial traction in early market entry simply by investing at and above market-leader levels. 

In fact, according to "Success Factors and Failure Points in Metabolic Product Launches," a recent study from Best Practices, LLC, more than half of companies (64%) from a benchmark class of 38 top companies favor spending between 101% - 150% of the market leader's investment level during product launch.

In addition to launch spending, recent market entries have illustrated that there are a critical core set of factors for metabolic products as well as other therapeutic areas: differentiation, defining a target patient population, thought leader engagement, education of key stakeholders, demonstrating value, and use of new technologies.

"Success Factors and Failure Points in Metabolic Product Launches" explores each aspect of this framework for launch success and provides a metabolic segment as well as a data segment representing other therapeutic areas combined.  This comprehensive launch study delivers qualitative and quantitative data on differentiation, pricing, physician and thought leader education, payer and formulary access, launch readiness, res
'/>"/>

SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Study Explores Utilization Trends for Prostate Cancer Treatments
2. Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI
3. Kuros Completes Patient Recruitment in its European Clinical Study With KUR-023, its Novel Dural Sealant Product Candidate
4. New Study Shows Modified Citrus Pectin Activates Powerful Immune Responses
5. Ultragenyx Initiates Phase 1 Clinical Study of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Muscle Wasting Disease
6. Comparative Study Confirms Enox Biopharmas Antimicrobial Superiority to Commercially Available Silver Coated Catheters
7. Allergy Technologies LLC Provides Over $100,000 in a Research Grant to The Ohio State University for the Study of Bed Bugs
8. Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
9. BridgePoint Medical Announces US IDE Approval and First Patient Enrollment of Peripheral Chronic Total Occlusion Study
10. Study Shows That Salt Lake City Based Company Has Program That Enhances Brain Activity
11. Apnex Medical, Inc. Receives FDA Approval for Pivotal Clinical Study for Obstructive Sleep Apnea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... LAWRENCE, Mass. , Dec. 22, 2014 /PRNewswire/ ... a leading manufacturer of innovative dialysis products, announced ... (FDA) has cleared its System One™ to perform ... sleeping, known as home nocturnal hemodialysis. NxStage,s® System ... cleared by the FDA for this indication. ...
(Date:12/22/2014)... LUXEMBOURG , Dec. 22, 2014  ConvaTec, a ... Paul Moraviec has been appointed Interim Chief Executive Officer ... Mr. Moraviec succeeds Ken Berger .  "The Board ... service in leading ConvaTec over the past three years," ... Board of Directors.  "We are confident that the company ...
(Date:12/22/2014)... , Dec, 22, 2014  Eiger BioPharmaceuticals ... 2a study of lonafarnib in patients with chronic ... conducted at the National Institutes of Health (NIH) ... .  The double-blinded, randomized, placebo-controlled, dose ascending study ... daily and 200 mg twice daily for 28 ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... , a leading provider of therapeutic drug monitoring and ... today the appointment of David Cohen to Chief Operating ... responsible for new business analysis and development to expand ... Millennium,s legislative initiatives and community outreach programs. ...
... Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following webcast:What: ... presented at ESCWhen: , Wednesday, September 1, 2010 at 4:00 ... Live on the Internet.  Simply log onto our Web site listed ... a replay of the webcast will be available for a limited ...
Cached Medicine Technology:Millennium Laboratories Announces New Chief Operating Officer David Cohen 2
(Date:12/24/2014)... As 2014 draws to a close, ... investing time and money into a new or tankless ... specializes in tankless and eco-friendly products or service. Greenstar ... heater in 2015 to research “green” and environmentally friendly ... Home Services specializes in eco-friendly and environmentally conscious ...
(Date:12/24/2014)... York (PRWEB) December 24, 2014 In ... the United States rode bicycles, hand cycles and recumbent ... D.C. in the inaugural CanAm Veterans’ Challenge . ... non-profit World T.E.A.M. Sports about this inspiring ride, is ... more than 50 full color photographs taken during the ...
(Date:12/24/2014)... 23, 2014 (HealthDay News) -- Each year, more than ... the United States occur because of extreme heat conditions, ... study finds that heat stroke is the leading cause ... as kidney failure and urinary tract infections, also put ... soar. The new data should help health care ...
(Date:12/24/2014)... -- Though most patients with obsessive-compulsive disorder (OCD) can ... percent to 20 percent have a form of the ... However, patients with this so-called "refractory OCD" do ... brain surgery that disables certain brain networks believed to ... patients most likely to benefit from the surgery, known ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 B. E. ... to healthcare providers, has been retained to lead a ... Tri-City Medical Center in Oceanside, Calif. The top ... B. E. Smith has recently placed more than 900 ... is a community owned, 397-bed, Gold Seal-approved, full-service acute-care ...
Breaking Medicine News(10 mins):Health News:Greenstar Home Services Offers Tankless Water Heater Advice to Local Homeowners 2Health News:New Commemorative Book Celebrates CanAm Veterans’ Challenge Bike Ride 2Health News:New Commemorative Book Celebrates CanAm Veterans’ Challenge Bike Ride 3Health News:Heat Stroke, Kidney Failure Help Drive Illnesses From Extreme Heat 2Health News:Scans May Spot People Who'll Benefit From Surgery for OCD 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 3
... Executive ... Chairman, SOUTH SAN ... company focused on the discovery,and development of drugs for major medical needs ... will step down today as President and Chief Executive Officer to,pursue another ...
... SAN DIEGO, Oct. 1 Amylin Pharmaceuticals,Inc. ... the U.S. Food and Drug,Administration (FDA) has ... pen-injector devices for administering SYMLIN(R),(pramlintide acetate) injection. ... dosing to improve mealtime glucose control. ...
... Presented at ERS 17th Annual Congress -, ... Inc.,today announced the submission of a pre-market approval ... (FDA) requesting regulatory,approval to market the Emphasys endobronchial ... Zephyr EBV is a minimally invasive and potentially,reversible ...
... have been homeless for any period of time after ... problems accessing health care than those with stable housing ... of Archives of Pediatrics & Adolescent Medicine, one of ... any period of time after leaving the foster care ...
... 1 Highlands Behavioral,Health System, a UHS facility, ... of Excellence for teens in crisis. The new ... Highlands Behavioral,Health ( http://www.highlandsbhs.com ) in Littleton, Colo. ... said the,Adolescent Center of Excellence represents an expansion ...
... was recently announced,as a silver winner in ... by,ComPsych Corporation. Concentra was selected based on ... achieved results. Concentra, a leader in ... commitment to better health and wellness among ...
Cached Medicine News:Health News:Renovis Announces Management Changes 2Health News:Renovis Announces Management Changes 3Health News:Renovis Announces Management Changes 4Health News:Renovis Announces Management Changes 5Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 2Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 3Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 4Health News:Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy 2Health News:Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy 3Health News:Poor health care access common among youth leaving foster system 2Health News:Poor health care access common among youth leaving foster system 3Health News:New Denver Area Program Developed For Teens in Crisis 2Health News:Concentra Honored With Silver Health at Work(SM) Award by ComPsych(R) Corp. 2
Polyester ribbons (3) impregnated with different OD values of conjugated Protein G...
Colloidal Gold Sol, 80 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Colloidal Gold Sol, 20 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
... Pachymeter [i.e., PalmScan P2000] device is ... which incorporates A-mode pulsed-echo ultrasound,technology, and ... measure the corneal thickness (CT) and,epithelium ... P2000 includes two software user,interfaces; a ...
Medicine Products: